Patient-Forward Rundown
Top headlines from this week to share with your patients:
Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Derm In The News: August 4-10
Keep up with the latest headlines in dermatology from the past week, including the FDA's approval of Lymphir for CTCL, L'Oreal buying stake in Galderma, and more.
Clemson News: Clemson Rural Health adds new provider, dermatology services to upstate clinics
Clemson Rural Health (CRH) is enhancing its service offerings to better serve rural and underserved populations by adding new professionals to its team. Jennilee Hill, NP, a family nurse practitioner with extensive experience in rural health and a specialization in dermatology, will join CRH this month, providing bilingual primary care and dermatology services at the Joseph F. Sullivan Center. Hill’s appointment reflects CRH’s ongoing efforts to address provider shortages in rural areas and expand its range of services, which include preventive, acute, and chronic care.
Reuters: L'Oreal acquires 10% stake in dermatology company Galderma
On August 5, L'Oréal announced it has acquired a 10% stake in Galderma Group. The shares were purchased from Sunshine SwissCo AG, Abu Dhabi Investment Authority, and Auba Investment Pte Ltd. The transaction, which will be financed through L'Oréal's cash and credit lines, is part of a broader strategic partnership between the 2 companies. The deal is expected to close in the near future.
Fierce Pharma: Citius notches first FDA approval, scoring with Lymphir for cutaneous T-cell lymphoma
Citius Pharmaceuticals has received FDA approval for Lymphir (denileukin diftitox-cxdl), a treatment for relapsed or refractory cutaneous T-cell lymphoma (CTCL) in patients who have undergone at least 1 prior systemic therapy. This marks Citius' first FDA-approved product. The approval follows a previous rejection due to the need for additional testing and controls. Lymphir, expected to launch in the next 5 months, is anticipated to impact the $300 to $400 million CTCL market.
PR Newswire: Lindus Health Unveils "All-in-One Dermatology CRO" Offering for Dermatology Clinical Trials
Lindus Health has introduced its new dermatology-focused contract research organization (CRO) and technology solution designed to streamline clinical trials for dermatological products. The "All-in-One Dermatology CRO" offers comprehensive services across various dermatological conditions, including acne, eczema, and skin cancers. The solution includes protocol development, regulatory compliance, participant recruitment, and data management. Lindus Health aims to expedite participant enrollment and trial execution. Their proprietary Citrus platform integrates multiple trial management technologies, supporting a range of study formats from traditional to virtual.
Have you seen any dermatology headlines this week that we may have missed? Share with us by emailing our team at DTEditor@mmhgroup.com.
Recent Videos
Related Content
